Category Archives: Nano Medicine

by Crista Leigh Farrell on December 4, 2020 4:24 pm

JOSEPH DESIMONE, the Sanjiv Sam Gambhir Professor in Translational Medicine and professor of chemical engineering, has been named the recipient of the 2019-20 Harvey Prize in science and technology in recognition of contributions in materials science, chemistry, polymer science and technology, nanomedicine, and 3D printing.

Joseph DeSimone

The Harvey Prize, the highest honor of the Technion-Israel Institute of Technology, recognizes breakthroughs in research that benefit humanity. The prize administrators said DeSimones work is a model for combining basic scientific discoveries with developments of industrial technologies that have a significant influence.

It is incredibly humbling to be selected for the Harvey Prize, said DeSimone. I have been fortunate in my career to work with brilliant students and colleagues to make advances in science and technology toward improving the human condition, and this is a tremendous honor and testament to our work together.

DeSimone, who joined the Stanford faculty in September, holds faculty appointments in the Department of Radiology, the Department of Chemical Engineering and, by courtesy, the Graduate School of Business. He previously held a joint appointment in chemistry and chemical engineering at the University of North Carolina at Chapel Hill and North Carolina State University.

An author of more than 350 scientific articles and an inventor on more than 200 issued patents, DeSimone is known for advances rooted in polymer science that have spawned new technologies and areas of research, as well as for translating discoveries made in his laboratory to the marketplace.

In the 1990s, he and students invented an environmentally friendly process for synthesizing high-performance plastics without the use of hazardous solvents. In 2004, DeSimone and his team invented a breakthrough nanoparticle fabrication process, leading to the launch of multiple medical products in clinical trials. In 2015, he and colleagues reported a breakthrough advance in polymer 3D printing, which led DeSimone to co-found Carbon, a company whose technology has enabled cutting-edge products in such industries as footwear, dental, medical, automotive and aerospace.

DeSimone is one of only 25 people elected to all three branches of the U.S. national academies (Sciences, Engineering and Medicine). In 2016, President Obama presented him with the National Medal of Technology and Innovation.

DeSimone joins other Stanford faculty members as a winner of the Harvey Prize, including RICHARD ZARE, DONALD KNUTH, ROGER KORNBERG, KARL DEISSEROTH and CARLA SHATZ.

DeSimone will receive the prize at the Technion in Haifa, Israel, in June if pandemic conditions permit.

Go here to read the rest:
Joseph DeSimone wins Harvey Prize in Science and Technology | The Dish - Stanford University News

OSLO, Norway, Nov. 19, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's management team will take place today in Oslo at 08.30 CET, see details below. A link to the webcast and the presentation is available from the company's homepage (www.nordicnanovector.com).

Lars Nieba, Interim CEO of Nordic Nanovector, said: "Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. Generating these data will require us to successfully navigate the latest challenges of increased COVID-19 restrictions. We remain confident in our ability to achieve this goal, aided by the protocol amendments, the possibility to reduce the patient sample, and all the other measures we are actively implementing to drive patient recruitment into PARADIGME."

Q3'2020 Highlights

Events after Q3'2020

Financial Highlights

(Figures in brackets = same period 2019 unless otherwise stated)

Outlook

The company continues to target the readout of three-month top line data from PARADIGME in H2'2021. Approval of protocol amendments is proceeding as planned and completed in the best-recruiting countries, and other initiatives to increase the rate of enrolment are underway. The company also targets the readout of three-month top line data from the second cohort of the Archer-1 trial in H1'2021.

However, the impact of the COVID-19 pandemic on patient recruitment has worsened in light of the emergence of a second wave resulting in severe travel restrictions being implemented in the various countries where we are executing our clinical studies. These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. Several proactive actions have been taken to minimize the impact of these travel restrictions which could blunt further delays in completing enrolment and delivering preliminary results as targeted.

The company has taken steps to conserve cash and following the recent successful private placement, Nordic Nanovector has a cash runway that extends into Q3'2021.

Despite the challenging times, the many positive actions the company has made in the last nine months have improved the prospects of delivering pivotal results from PARADIGME in H2'2021.

The company continues to believe that, if positive, these trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin as a highly promising new targeted therapy that can address the unmet needs of R/R FL patients.

Presentation and live webcast Q3 2020 results

A presentation and live webcast by Nordic Nanovector's management team will take place today at 8:30 am CET.

The webcast can be accessed from http://www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation is available at http://www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

Tel: +44 203 926 8535

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Further information can be found at http://www.nordicnanovector.com .

Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--results-for-the-third-quarter-2020,c3239830

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-results-for-the-third-quarter-2020-301176750.html

SOURCE Nordic Nanovector

Company Codes: Bloomberg:NANO@NO, ISIN:NO0010597883, Oslo:NANO, RICS:NANO.OL

Visit link:
Nordic Nanovector ASA: Results for the Third Quarter 2020 - BioSpace

The global Healthcare Nanotechnology (Nanomedicine) Market study offers a compilation of the current, historical, and future outlook of the industry as well as the factors responsible for market growth. With a SWOT analysis, the business study highlights the weaknesses, strengths, opportunities, and threats of each Healthcare Nanotechnology (Nanomedicine) Market player in a comprehensive way.

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-64780?utm_source=SA/technoweekly

Under the COVID-19 outbreak analysis, this report provides analysis of import, supply chain, and export to future influence on the industry and regional government policies. Enterprise competition pattern, detailed analysis about market status, advantages and disadvantages of enterprise products, macroeconomic policies and regional industrial layout characteristics, industry development trends have also been included. The trends of product sales channel will be offered as well.

Considering COVID-19, this report offers a complete and exhaustive analysis on how the epidemic has pushed transformation and reform in the industry. The market study can help understand the market expansion and strategies for business accordingly. In the strategy analysis, it gives insights from market positioning marketing channel to potential growth strategies, thereby providing an in-depth analysis for new entrants or existing competitors in the Healthcare Nanotechnology (Nanomedicine) industry.

Key Players: Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd..

The market analysis on the Healthcare Nanotechnology (Nanomedicine) offers a birds eye view of the current proceeding within the Healthcare Nanotechnology (Nanomedicine) Market. The market analysis report has incorporated an analysis of various factors that augment the markets growth. It constitutes restraints, trends, and drivers that transform the market in either a negative orpositive manner.

Healthcare Nanotechnology (Nanomedicine) Market

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-64780?utm_source=SA/technoweekly

This market analysis also offers the scope of different segments and applications that can actually impact the market in the future. The thorough information is based on present trends and historic milestones. The market analysis mentions the volume of sales by region from 2015 to 2026. A thorough evaluation of the limitations included in the market analysis portrays the drivers and gives room for strategic planning.

Global Healthcare Nanotechnology (Nanomedicine) Market: Segment Analysis

Each type offers information about return sover the forecast period of 2018 to 2028. The sales method segment also offers revenue by volume and sales over the forecast period of 2018 to 2028. Understanding the segments helps in classifying the importance of various factors that support market growth.

Following are the segmentation covered by the market study: By Application (Drug Delivery, Biomaterials, Active Implants, Diagnostic Imaging, Tissue Regeneration), By Disease (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases and Other Diseases)

Global Healthcare Nanotechnology (Nanomedicine) Market: Regional Analysis

The market analysis report includes a thorough study of various factors that determine regional growth such as environmental, economic, social political status, technology, and region. Market analysis has studied the data of sales, revenue, and manufacturers of each region. The market analysis provides region-wise volume and revenue for the forecast period of 2016 to 2028. This market analysis will support the market participants to understand the potential worth of investment in a particular region.

Region- wise Analysis of the Global Healthcare Nanotechnology (Nanomedicine) Market covers: North America Europe Asia Pacific Middle East and Africa South America

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-64780?utm_source=SA/AF

Global Healthcare Nanotechnology (Nanomedicine) Market: Competitive Landscape

This market analysis report classifies numerous key manufacturers of the industry. It supports the reader in understanding the policies and collaborations that the industry participants are focusing on in order to combat competition in the industry. The comprehensive market analysis offers a note worthy microscopic look at the industry. The market analysis can classify the footprints of the manufacturers by giving the global revenue of manufacturers and sales by manufacturers, and the global price of manufacturers over the forecast period of 2018 to 2028.

Major Aspects covered in the Report are

Further, the report provides niche insights for a decision about every possible segment, helping in the strategic decision-making process and market size estimation of the Healthcare Nanotechnology (Nanomedicine) Market on a regional and global basis. Unique research designed for market size estimation and forecast is used for the identification of major companies operating in the market with related developments. The report has an exhaustive scope to cover all the possible segments, helping every stakeholder in the Healthcare Nanotechnology (Nanomedicine) Market.

Reasons for buying this report:

Why Do Companies Trust QMI?

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Excerpt from:
Healthcare Nanotechnology (Nanomedicine) Market is Slated To Grow Rapidly In The Coming Years (2020 2028) - TechnoWeekly

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the SEC) relating to a proposed initial public offering of its American Depositary Shares (ADSs), representing ordinary shares, in the United States (the U.S. Offering), and a concurrent private placement of its ordinary shares in Europe (including France) and other countries outside of the United States (the European Private Placement, and together with the U.S. Offering, the Global Offering). All securities to be sold in the Global Offering will be offered by the Company. The number of ordinary shares to be represented by each ADS, the number of ADSs and ordinary shares to be offered and the price range for the proposed Global Offering have not yet been determined. The Company has applied to list its ADSs on the Nasdaq Global Market under the ticker symbol NBTX. The Companys ordinary shares are listed on Euronext Paris under the symbol NANO.

Jefferies LLC is acting as global coordinator for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are also acting as joint book-running managers for the U.S. Offering. Gilbert Dupont is acting as manager for the European Private Placement.

The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at ol-prospectusrequest@ubs.com.

A registration statement relating to the securities referred to herein has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. The registration statement can be accessed by the public on the website of the SEC.

About NANOBIOTIX

Nanobiotix is a French, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. Nanobiotixs novel, proprietary lead technology, NBTXR3, is being evaluated in locally-advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Nanobiotix is also running an Immuno-Oncology development program. The Companys headquarters are in Paris, France, with a U.S. affiliate in Cambridge, Massachusetts, and European affiliates in France, Spain and Germany.

Read more here:
NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States - Business Wire

Global Oral Contrast Agent Market research report is in-depth study on the market size, growth, trends, market share, as well as detailed industry analysis. The research report offers the study of market size of the Oral Contrast Agent Market in terms of value of the year 2020 and estimated market size of 2026. The study offers the analysis of market performance for the forecast period 2015-2026, accounting on the basis of various growth determinants over the last five years.

Request Free Sample Report athttps://reportocean.com/industry-verticals/sample-request?report_id=QY809

The key players profiled in the research study of Oral Contrast Agent Market include:The major vendors covered:GE Healthcare (US)Bracco Imaging (Italy)Bayer HealthCare (Germany)Guerbet (France)Lantheus (US)Daiichi Sankyo (Japan)Unijules Life Sciences (India)J.B. Chemicals and Pharmaceuticals (India)Spago Nanomedicine (Sweden)Taejoon Pharm (South Korea)Jodas (India)Magnus Health (India)

The study on the global Oral Contrast Agent Market for all relevant companies dealing with the Oral Contrast Agent Market and related profiles include data in quantitative terms, product portfolio, and business strategy along with active tracking of recent developments. The research study is a wholesome collection of primary and secondary data collected and analysed from valuable information sources. The market forecast is based on data ranging from the year 2015 until 2026. For easy understanding, the study includes data representation in the form of various graphs and tables.

The main sources of gathering relevant data are industry experts from the Oral Contrast Agent Market industry, including processing organizations, management organizations and analytical services providers that actively contribute in the value chain of the Oral Contrast Agent Market. To compile the analytical study, we interviewed various sources and collected qualitative and quantitative information with key focus to determine future prospects of the Oral Contrast Agent Market. While, the secondary research studies include critical information about the industrial value chain, strategical developments by key companies and studying annual reports of the market players while tracking their key initiatives and contribution in market share.

The major objective of the Oral Contrast Agent Market study are:

To analyse Oral Contrast Agent Market status, key players, key market, growth opportunity and future forecast.

To offer the Oral Contrast Agent Market development in North America, Europe, China, Japan and Southeast Asia.

To strategically profile the companies dealing in Oral Contrast Agent Market and broadly study their strategic development plans to acquire key share in the global marketplace.

The research report provides data information and detailed profile analysis of leading companies of the Oral Contrast Agent Market.

Table of Content

1 Study Coverage1.1 Oral Contrast Agent Product Introduction1.2 Market Segments1.3 Key Oral Contrast Agent Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Oral Contrast Agent Market Size Growth Rate by Type1.4.2 Barium-based Contrast Media1.4.3 Iodinated Contrast Media1.4.4 Gadolinium-based Contrast Media1.4.5 Microbubble Contrast Media1.5 Market by Application1.5.1 Global Oral Contrast Agent Market Size Growth Rate by Application1.5.2 Cardiovascular Disorders1.5.3 Cancer1.5.4 Gastrointestinal Disorders1.5.5 Musculoskeletal Disorders1.5.6 Neurological Disorders1.5.7 Nephrological Disorders1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Oral Contrast Agent Market Size, Estimates and Forecasts2.1.1 Global Oral Contrast Agent Revenue 2015-20262.1.2 Global Oral Contrast Agent Sales 2015-20262.2 Global Oral Contrast Agent, Market Size by Producing Regions: 2015 VS 2020 VS 20262.2.1 Global Oral Contrast Agent Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Oral Contrast Agent Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Oral Contrast Agent Competitor Landscape by Players3.1 Oral Contrast Agent Sales by Manufacturers3.1.1 Oral Contrast Agent Sales by Manufacturers (2015-2020)3.1.2 Oral Contrast Agent Sales Market Share by Manufacturers (2015-2020)3.2 Oral Contrast Agent Revenue by Manufacturers3.2.1 Oral Contrast Agent Revenue by Manufacturers (2015-2020)3.2.2 Oral Contrast Agent Revenue Share by Manufacturers (2015-2020)3.2.3 Global Oral Contrast Agent Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Oral Contrast Agent Revenue in 20193.2.5 Global Oral Contrast Agent Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Oral Contrast Agent Price by Manufacturers3.4 Oral Contrast Agent Manufacturing Base Distribution, Product Types3.4.1 Oral Contrast Agent Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Oral Contrast Agent Product Type3.4.3 Date of International Manufacturers Enter into Oral Contrast Agent Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)4.1 Global Oral Contrast Agent Market Size by Type (2015-2020)4.1.1 Global Oral Contrast Agent Sales by Type (2015-2020)4.1.2 Global Oral Contrast Agent Revenue by Type (2015-2020)4.1.3 Oral Contrast Agent Average Selling Price (ASP) by Type (2015-2026)4.2 Global Oral Contrast Agent Market Size Forecast by Type (2021-2026)4.2.1 Global Oral Contrast Agent Sales Forecast by Type (2021-2026)4.2.2 Global Oral Contrast Agent Revenue Forecast by Type (2021-2026)4.2.3 Oral Contrast Agent Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Oral Contrast Agent Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)5.1 Global Oral Contrast Agent Market Size by Application (2015-2020)5.1.1 Global Oral Contrast Agent Sales by Application (2015-2020)5.1.2 Global Oral Contrast Agent Revenue by Application (2015-2020)5.1.3 Oral Contrast Agent Price by Application (2015-2020)5.2 Oral Contrast Agent Market Size Forecast by Application (2021-2026)5.2.1 Global Oral Contrast Agent Sales Forecast by Application (2021-2026)5.2.2 Global Oral Contrast Agent Revenue Forecast by Application (2021-2026)5.2.3 Global Oral Contrast Agent Price Forecast by Application (2021-2026)

6 North America6.1 North America Oral Contrast Agent by Country6.1.1 North America Oral Contrast Agent Sales by Country6.1.2 North America Oral Contrast Agent Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Oral Contrast Agent Market Facts & Figures by Type6.3 North America Oral Contrast Agent Market Facts & Figures by Application

7 Europe7.1 Europe Oral Contrast Agent by Country7.1.1 Europe Oral Contrast Agent Sales by Country7.1.2 Europe Oral Contrast Agent Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Oral Contrast Agent Market Facts & Figures by Type7.3 Europe Oral Contrast Agent Market Facts & Figures by Application

8 Asia Pacific8.1 Asia Pacific Oral Contrast Agent by Region8.1.1 Asia Pacific Oral Contrast Agent Sales by Region8.1.2 Asia Pacific Oral Contrast Agent Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Oral Contrast Agent Market Facts & Figures by Type8.3 Asia Pacific Oral Contrast Agent Market Facts & Figures by Application

9 Latin America9.1 Latin America Oral Contrast Agent by Country9.1.1 Latin America Oral Contrast Agent Sales by Country9.1.2 Latin America Oral Contrast Agent Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Oral Contrast Agent Market Facts & Figures by Type9.3 Central & South America Oral Contrast Agent Market Facts & Figures by Application

10 Middle East and Africa10.1 Middle East and Africa Oral Contrast Agent by Country10.1.1 Middle East and Africa Oral Contrast Agent Sales by Country10.1.2 Middle East and Africa Oral Contrast Agent Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Oral Contrast Agent Market Facts & Figures by Type10.3 Middle East and Africa Oral Contrast Agent Market Facts & Figures by Application

11 Company Profiles11.1 GE Healthcare (US)11.1.1 GE Healthcare (US) Corporation Information11.1.2 GE Healthcare (US) Description and Business Overview11.1.3 GE Healthcare (US) Sales, Revenue and Gross Margin (2015-2020)11.1.4 GE Healthcare (US) Oral Contrast Agent Products Offered11.1.5 GE Healthcare (US) Related Developments11.2 Bracco Imaging (Italy)11.2.1 Bracco Imaging (Italy) Corporation Information11.2.2 Bracco Imaging (Italy) Description and Business Overview11.2.3 Bracco Imaging (Italy) Sales, Revenue and Gross Margin (2015-2020)11.2.4 Bracco Imaging (Italy) Oral Contrast Agent Products Offered11.2.5 Bracco Imaging (Italy) Related Developments11.3 Bayer HealthCare (Germany)11.3.1 Bayer HealthCare (Germany) Corporation Information11.3.2 Bayer HealthCare (Germany) Description and Business Overview11.3.3 Bayer HealthCare (Germany) Sales, Revenue and Gross Margin (2015-2020)11.3.4 Bayer HealthCare (Germany) Oral Contrast Agent Products Offered11.3.5 Bayer HealthCare (Germany) Related Developments11.4 Guerbet (France)11.4.1 Guerbet (France) Corporation Information11.4.2 Guerbet (France) Description and Business Overview11.4.3 Guerbet (France) Sales, Revenue and Gross Margin (2015-2020)11.4.4 Guerbet (France) Oral Contrast Agent Products Offered11.4.5 Guerbet (France) Related Developments11.5 Lantheus (US)11.5.1 Lantheus (US) Corporation Information11.5.2 Lantheus (US) Description and Business Overview11.5.3 Lantheus (US) Sales, Revenue and Gross Margin (2015-2020)11.5.4 Lantheus (US) Oral Contrast Agent Products Offered11.5.5 Lantheus (US) Related Developments11.6 Daiichi Sankyo (Japan)11.6.1 Daiichi Sankyo (Japan) Corporation Information11.6.2 Daiichi Sankyo (Japan) Description and Business Overview11.6.3 Daiichi Sankyo (Japan) Sales, Revenue and Gross Margin (2015-2020)11.6.4 Daiichi Sankyo (Japan) Oral Contrast Agent Products Offered11.6.5 Daiichi Sankyo (Japan) Related Developments11.7 Unijules Life Sciences (India)11.7.1 Unijules Life Sciences (India) Corporation Information11.7.2 Unijules Life Sciences (India) Description and Business Overview11.7.3 Unijules Life Sciences (India) Sales, Revenue and Gross Margin (2015-2020)11.7.4 Unijules Life Sciences (India) Oral Contrast Agent Products Offered11.7.5 Unijules Life Sciences (India) Related Developments11.8 J.B. Chemicals and Pharmaceuticals (India)11.8.1 J.B. Chemicals and Pharmaceuticals (India) Corporation Information11.8.2 J.B. Chemicals and Pharmaceuticals (India) Description and Business Overview11.8.3 J.B. Chemicals and Pharmaceuticals (India) Sales, Revenue and Gross Margin (2015-2020)11.8.4 J.B. Chemicals and Pharmaceuticals (India) Oral Contrast Agent Products Offered11.8.5 J.B. Chemicals and Pharmaceuticals (India) Related Developments11.9 Spago Nanomedicine (Sweden)11.9.1 Spago Nanomedicine (Sweden) Corporation Information11.9.2 Spago Nanomedicine (Sweden) Description and Business Overview11.9.3 Spago Nanomedicine (Sweden) Sales, Revenue and Gross Margin (2015-2020)11.9.4 Spago Nanomedicine (Sweden) Oral Contrast Agent Products Offered11.9.5 Spago Nanomedicine (Sweden) Related Developments11.10 Taejoon Pharm (South Korea)11.10.1 Taejoon Pharm (South Korea) Corporation Information11.10.2 Taejoon Pharm (South Korea) Description and Business Overview11.10.3 Taejoon Pharm (South Korea) Sales, Revenue and Gross Margin (2015-2020)11.10.4 Taejoon Pharm (South Korea) Oral Contrast Agent Products Offered11.10.5 Taejoon Pharm (South Korea) Related Developments11.1 GE Healthcare (US)11.1.1 GE Healthcare (US) Corporation Information11.1.2 GE Healthcare (US) Description and Business Overview11.1.3 GE Healthcare (US) Sales, Revenue and Gross Margin (2015-2020)11.1.4 GE Healthcare (US) Oral Contrast Agent Products Offered11.1.5 GE Healthcare (US) Related Developments11.12 Magnus Health (India)11.12.1 Magnus Health (India) Corporation Information11.12.2 Magnus Health (India) Description and Business Overview11.12.3 Magnus Health (India) Sales, Revenue and Gross Margin (2015-2020)11.12.4 Magnus Health (India) Products Offered11.12.5 Magnus Health (India) Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)12.1 Oral Contrast Agent Market Estimates and Projections by Region12.1.1 Global Oral Contrast Agent Sales Forecast by Regions 2021-202612.1.2 Global Oral Contrast Agent Revenue Forecast by Regions 2021-202612.2 North America Oral Contrast Agent Market Size Forecast (2021-2026)12.2.1 North America: Oral Contrast Agent Sales Forecast (2021-2026)12.2.2 North America: Oral Contrast Agent Revenue Forecast (2021-2026)12.2.3 North America: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.3 Europe Oral Contrast Agent Market Size Forecast (2021-2026)12.3.1 Europe: Oral Contrast Agent Sales Forecast (2021-2026)12.3.2 Europe: Oral Contrast Agent Revenue Forecast (2021-2026)12.3.3 Europe: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Oral Contrast Agent Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Oral Contrast Agent Sales Forecast (2021-2026)12.4.2 Asia Pacific: Oral Contrast Agent Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Oral Contrast Agent Market Size Forecast by Region (2021-2026)12.5 Latin America Oral Contrast Agent Market Size Forecast (2021-2026)12.5.1 Latin America: Oral Contrast Agent Sales Forecast (2021-2026)12.5.2 Latin America: Oral Contrast Agent Revenue Forecast (2021-2026)12.5.3 Latin America: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Oral Contrast Agent Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Oral Contrast Agent Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Oral Contrast Agent Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Oral Contrast Agent Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Oral Contrast Agent Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Oral Contrast Agent Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

Inquire or Share Your Questions If Any before Purchasing This Report:https://reportocean.com/industry-verticals/sample-request?report_id=QY809

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

More:
Latest Innovative Report on Oral Contrast Agent Market | Research Report Explores The Trade Trends For The Forecast 2020 2026 - The Daily...

KANAZAWA, Japan, Nov. 17, 2020 /PRNewswire/ --The 4th NanoLSI Symposium will be a virtual meeting covering bio-imaging, sensing, and manipulation for medical science. The Nano Life Science Institute (WPI-NanoLSI) was established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology.

Symposium website

https://nanolsi.kanazawa-u.ac.jp/en/4th-sympo/

Flyer

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2020/11/NanoLSI_symposium_2020.jpg

Program details

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2020/11/program.pdf

Nano Life Science Institute (WPI-NanoLSI) aims to acquire a fundamental understanding of various life phenomena, such as development, disease, and aging at the nano-level through transdisciplinary research of Nanometrology, Life Science, Supramolecular Chemistry, and Computational Science.

To further develop interdisciplinary research, the WPI-NanoLSI has organized annual international symposia to build new collaborative relationships with researchers across the world.

This year's fourth symposium will be held online because of restrictions to travel due to the COVID-19 pandemic. To facilitate research exchange that is only possible through online, the WPI-NanoLSI has invited prominent researchers from Europe, North America, and Asia to give talks during the symposium, where each session is scheduled according to the local times of the speakers.

This is an excellent opportunity to gain valuable insights into the latest research findings in bio-imaging, sensing, and manipulation for medical science.

Details

Date: 26 -27 November 2020

Format: Virtual conference (via Zoom) that is free of charge

Timetable

Thursday 26 November

07:40 07:50 (JST) Opening remarks

08:00 10:00 (JST) 1st session

Molecular and cellular dynamics in biological regulation and regenerative medicine

Chair: Prof. Kunio MATSUMOTO/ NanoLSI/CRI

Speakers: Prof. Simon SCHEURING/ Weill Cornell Medicine

Assoc. Prof. Yusuke MIYANARI/ NanoLSI/CRI

Prof. Kenneth S. Zaret/ University of Pennsylvania

Prof. Takanori TAKEBE/ Tokyo Medical and Dental University

10:00 11:00 (JST). Virtual poster session

*Need Separate registration. Please see website

13:30 15:30 (JST) 2nd session

Chemistry-Driven Challenges: from Molecule to Nano/Microscale

Chair: Assoc.Prof. Satoshi ARAI/ NanoLSI

Speakers: Prof. Tomoki OGOSHI/ Kyoto University

Assoc. Prof. Toshinori FUJIE/ Tokyo Institute of Technology

Assoc. Prof. Etsuo SUSAKI/ The University of Tokyo

Prof. Susumu KITAGAWA/ Kyoto University

15:30 16:00 (JST) Video session #1

17:00 19:00 (JST) 3rd session

Nano-scale approaches to physiological and pathological phenomena

Chair: Prof. Toshio ANDO/ NanoLSI

Speakers: Dr. Nobuo NODA/ Institute of Microbial Chemistry

Prof. Noriyuki KODERA/ NanoLSI

Assoc. Prof. Shinji WATANABE/ NanoLSI

Prof. Victor SHAHIN/ University of Mnster

19:00 19:30 (JST) Video session #2

Friday 27 November

10:00 12:00 (JST) 4th session

Imaging approaches to explore cancer biology

Chair: Prof. Masanobu OSHIMA/ NanoLSI/CRI

Speakers: Asst. Prof. Keehoon JUNG/Seoul National University College of Medicine

Prof. Takeshi IMAMURA/ Ehime University

Asst. Prof. Ann-Marie CHACKO/ Duke-NUS Medical School

Prof. Masanobu OSHIMA/ NanoLSI/CRI

12:00 12:05 (JST) Closing remarks

Further information

About WPI nanoLSI Kanazawa University Hiroe YonedaVice Director of Public AffairsWPI Nano Life Science Institute (WPI-NanoLSI)Kanazawa UniversityKakuma-machi, Kanazawa 920-1192, JapanEmail: nanolsi-office@adm.kanazawa-u.ac.jpTel: +81 (76) 234-4550

About Nano Life Science Institute (WPI-NanoLSI)

https://nanolsi.kanazawa-u.ac.jp/en/

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

SOURCE Kanazawa University

See original here:
Kanazawa University research: The Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University is organizing the 4th NanoLSI Symposium on 26 and...